Lexocy-A Tablet is a combination medication containing Acetylcysteine 300 mg and Ambroxol 30 mg, primarily indicated for the management of respiratory conditions characterized by excessive or thick mucus production, such as chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and other pulmonary disorders. Acetylcysteine acts as a mucolytic agent by breaking down the disulfide bonds in mucus glycoproteins, thereby reducing mucus viscosity and facilitating easier expectoration. Ambroxol, a mucokinetic and secretolytic agent, enhances the production and clearance of respiratory tract secretions by stimulating surfactant synthesis and improving ciliary activity, which aids in mucus transport. The synergistic effect of these two active ingredients helps in relieving symptoms like cough and congestion, promoting better airway clearance and improving respiratory function. Lexocy-A is typically administered orally, with dosage and duration tailored according to the severity of the condition and patient response. It is generally well tolerated, though caution is advised in patients with hypersensitivity to either component, and monitoring is recommended in those with hepatic or renal impairment. Lexocy-A Tablet should be used under medical supervision to ensure optimal therapeutic outcomes and minimize potential adverse effects.